NYSE American - Delayed Quote • USD
Scorpius Holdings, Inc. (SCPX)
At close: May 28 at 4:00 PM EDT
After hours: May 28 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | 0 | 0 | -0.63 | -0.46 |
| Low Estimate | 0 | 0 | -0.63 | -0.46 |
| High Estimate | 0 | 0 | -0.63 | -0.46 |
| Year Ago EPS | -0.47 | -0.53 | -1.74 | -0.63 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | -- | 20.6M | 35.1M |
| Low Estimate | -- | -- | 20.6M | 35.1M |
| High Estimate | -- | -- | 20.6M | 35.1M |
| Year Ago Sales | -- | -- | 7M | 20.6M |
| Sales Growth (year/est) | -- | -- | 194.50% | 70.40% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.43 | -0.45 | -0.35 | -0.22 |
| EPS Actual | -0.47 | -0.53 | -0.5 | -0.21 |
| Difference | -0.04 | -0.08 | -0.15 | 0.01 |
| Surprise % | -9.30% | -17.80% | -42.90% | 4.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -0.63 | -0.46 |
| 7 Days Ago | 0 | 0 | -0.63 | -0.46 |
| 30 Days Ago | 0 | 0 | -0.63 | -0.46 |
| 60 Days Ago | 0 | 0 | -0.63 | -0.46 |
| 90 Days Ago | 0 | 0 | -0.63 | -0.46 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SCPX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 7.90% |
| Next Qtr. | -- | -- | -- | 10.20% |
| Current Year | 63.80% | -- | -- | 4.80% |
| Next Year | 27.00% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | Brookline Capital: Buy to Hold | 5/1/2023 |
| Downgrade | Maxim Group: Buy to Hold | 4/3/2023 |
| Initiated | Cantor Fitzgerald: Overweight | 3/3/2021 |
Related Tickers
NBY NovaBay Pharmaceuticals, Inc.
0.1410
+6.98%
MBIO Mustang Bio, Inc.
0.1885
-10.20%
KTRA Kintara Therapeutics, Inc.
0.1879
+11.85%
ONCO Onconetix, Inc.
0.1639
-9.90%
ALLR Allarity Therapeutics, Inc.
0.5752
-0.10%
TOVX Theriva Biologics, Inc.
0.2710
-11.44%
BDRX Biodexa Pharmaceuticals Plc
1.0800
+4.85%
VIRI Virios Therapeutics, Inc.
0.2349
+12.18%
NKGN NKGen Biotech, Inc.
1.5000
+5.63%
GTBP GT Biopharma, Inc.
3.5300
-4.08%